MyFinsight
Home
Blog
About
Comprehensive loss
-$22,864K
(-68.76%↓ Y/Y)
Net loss
-$22,864K
(-68.76%↓ Y/Y)
Net loss before
income taxes
-$22,864K
(-68.76%↓ Y/Y)
Interest income and other
income, net
$882K
(-57.92%↓ Y/Y)
Manufacture And Supply
Revenue
$11,911K
(24.29%↑ Y/Y)
License And Royalty
Revenue
$1,326K
(58.05%↑ Y/Y)
Co Development And
Research Fees
$582K
(53.97%↑ Y/Y)
Loss on
extinguishment of debt
-$11,683K
Loss from operations
-$8,223K
(27.67%↑ Y/Y)
Interest expense
$2,807K
(0.93%↑ Y/Y)
Interest expense related
to royalty...
$972K
(-32.22%↓ Y/Y)
Revenues
$13,819K
(38.15%↑ Y/Y)
Interest expense related
to the sale of...
$61K
(0.00%↑ Y/Y)
Total costs and
expenses
$22,042K
(3.14%↑ Y/Y)
Selling, general and
administrative
$14,063K
(10.69%↑ Y/Y)
Manufacture and supply
$4,017K
(-11.93%↓ Y/Y)
Research and development
$3,962K
(-3.48%↓ Y/Y)
Back
Back
Income Statement
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)
source: myfinsight.com